UnitedHealth (UNH) shares are at $417.64, consolidating after the Q2 2026 beat ( $6.38 vs $4.92, +29.8%) and guidance raise (FY2026 $19.50-$20.00). at 18.67 (Neutral regime) and 10Y yield at 4.64% create a cautious backdrop. Fundamentally strong: FY2026 estimates rose 7.3% in 30 days to $19.81, FY2027 up 8.1% to $22.44. Analyst actions are positive with five target raises post-earnings (Morgan Stanley $529, KeyBanc $500, JPMorgan $516, Mizuho $493, Barclays $441). Zacks upgraded to Strong Buy. Technically, price remains above rising ($403.93) and ($351.74), confirming the long-term uptrend. However, near-term momentum has weakened: histogram is -2.18 and widening, dropped to 49.6, and is declining. Volume is 62% of 20-day average, indicating institutional profit-taking. Insider activity is neutral with no material transactions. The next earnings is 91 days away, reducing event risk. The key risk is elevated commercial medical costs delaying margin recovery. The fundamental thesis is robust, but the technical setup suggests patience. The recommendation is HOLD for the near term, BUY over six months, and STRONG BUY for the long term.
投资判断
实时价格
$417.64
推荐分数
83%
83%
置信度
85%
85%
各期限展望
1个月
持有
短线
6个月
买入
中期
1年
强力买入
长期
核心催化
The Q2 earnings beat and guidance raise remain the dominant catalyst, with subsequent analyst target raises reinforcing the fundamental story despite near-term technical digestion.
Standard position size is appropriate given the moderate . Long-term investors can maintain full strategic allocations. Tactical traders may reduce size slightly due to negative and technical consolidation.
投资逻辑快照
什么情况涨
UNH's Q2 earnings beat and raised guidance confirm the earnings recovery trajectory. The raised FY2026 outlook implies 13-16% growth, with further upside from Optum's AI efficiencies and commercial margin recovery in 2027. The stock offers a compelling 6.0% FCF yield and 2.21% dividend yield with low beta (0.63). Analyst targets have been raised to $500-$529, supporting 16-26% upside. Estimate revisions are strongly positive, with FY2027 up 8.1% in 30 days and 8 upward revisions with 0 downgrades. The defensive nature provides resilience in a cautious market regime.
什么情况跌
The stock's failure to hold the initial 10% post-earnings gain and subsequent decline below the is a technical warning that good news may be fully priced. Commercial medical costs remain elevated, and margin recovery may be delayed beyond 2027. Medicare Advantage membership declined by ~525k in Q2, with further losses expected. Short interest at 2.13% is modest but could rise if sentiment turns. Rising rates (10Y at 4.64%) could compress multiples, and the forward of 18.6x on FY2027 is above the 5-year median, leaving less room for error.
A weekly close below the 50-day ($403.93) would invalidate the short-term uptrend and suggest the earnings optimism has faded. From a fundamental perspective, a future quarterly report showing worse-than-expected medical cost ratios or a guidance cut would be the primary invalidation.
Medical utilization spike exceeding expectations, delaying commercial margin recovery further.
Medicare Advantage membership decline beyond 1 million in 2026, constraining revenue growth.
Regulatory actions such as Medicaid fraud lawsuits, drug pricing reforms, or changes to Medicare Advantage funding.
Sharp rise in interest rates (10Y above 5%) compressing growth stock multiples, though UNH's moderate valuation and low beta provide relative resilience.
接下来关注
下一次财报：2026年10月27日
The Q2 earnings beat and guidance raise remain the dominant catalyst, with subsequent analyst target raises reinforcing the fundamental story despite near-term technical digestion.
信号仪表盘
决策输入
6 个信号
基本面
13.8%
距分析师均值目标空间
At $417.64, UNH trades at a forward of 18.6x on FY2027 consensus of $22.44, slightly above the 5-year median of 19x but justified by accelerated earnings growth. The ratio of 1.35 is attractive relative to projected growth (13.8% YoY in FY2027). FCF yield of 6.0% is compelling for a stable compounder. of 17.5x is reasonable given Optum's higher-margin profile. Relative to peers (median forward ~18x), UNH commands a justified premium. Analyst median target of $490 implies 17.3% upside; the high target of $529 suggests 26.7% upside.
技术面
Bearish
趋势质量
Long-term uptrend intact: price ($417.64) is 18.7% above the rising 200-day ($351.74) and 3.4% above the 50-day ($403.93). The / spread is positive and expanding (golden cross confirmed). However, price closed below the ($424.44), indicating near-term consolidation. The overall trend is bullish but has lost near-term momentum.
财报
91天
Turning Positive
Q2 2026 of $6.38 beat consensus by 29.8%, driven by stronger-than-expected medical cost ratio improvement and Optum growth. FY2026 guidance raised to $19.50-$20.00.
新闻
Mixed-Bullish
新闻基调
The Q2 earnings beat and guidance raise remain the dominant catalyst, with subsequent analyst target raises reinforcing the fundamental story despite near-term technical digestion.
宏观
Neutral
4.64% 10Y / 18.7 VIX
at 18.67 places markets in a cautious regime, favoring defensive stocks with low beta and strong cash flows like UNH. The 10Y yield at 4.64% pressures high-multiple stocks, but UNH's moderate forward (~18.6x on FY2027 ) and high FCF yield buffer the impact.
稳定性
Stable Compounder
Core Anchor
UnitedHealth's integrated model combining health insurance with Optum generates substantial free cash flow (22.8B, 6.0% FCF yield) and a low beta of 0.63. The Q2 2026 earnings beat (29.8% surprise) and raised FY2026 guidance to $19.50-$20.00 reinforce earnings recovery. Estimate revisions are strongly upward: FY2027 raised to $22.44, with 8 upward revisions and 0 down in 30 days. The forward of 18.6x on FY2027 is reasonable given 13-16% growth. The durable competitive advantage, moderate valuation, and defensive profile make it a core anchor. Drawdown risk is medium due to Medicare membership declines and regulatory overhangs, but strong cash flows and pricing power provide resilience.
分析师目标区间
均值目标
$475.23
高低目标
$313 / $529
分析师中值目标
$490.00
共识区间
$313 - $529
— 位分析师
Mean
$313$475$529
市场共识
The spread between low ($313) and high ($529) targets indicates uncertainty about commercial costs and regulatory risk, but the median target of $490 (17.3% upside from $417.64) and recent upward revisions show growing conviction. The consensus is heavily positive: 6 Strong Buy, 16 Buy, 5 Hold, 0 Sell/Strong Sell.
筹码脉冲
内部人信号
Neutral
净偏向
No recent activity
内部人持股
0.2%
机构持股
86.2%
解读
Insider activity provides no directional signal.
重要活动
Only three small transactions from directors dated 147-149 days ago, likely tax-related or gifts. No open-market buying or selling.
市场背景
行业
Healthcare Plans
Bullish
情绪
42
跟踪股票
1
分组
industry
Healthcare Plans 行业 当前情绪为 Bullish，板块平均评分约 83 分，资金偏好与评分正在走弱，且leadership is still concentrated。
轮动线索
Healthcare Plans 行业 组内平均推荐分数在回落，说明短线资金偏好正在减弱。
当前组内偏多评级 1 只，偏空评级 0 只，可见情绪主导方向为 Bullish。
重点龙头股
相关龙头股
当前还没有其他已跟踪龙头股。
主题
Value-Based Care
评分: 85
Bullish
Capital continues rotating into healthcare models focused on outcomes and cost efficiency. UNH's Optum segment is the gold standard, validated by Q2 results showing improved Medicare margins and AI-driven efficiencies. The theme is strengthening as UNH's execution contrasts with peers' margin challenges. The market's acceptance of Medicare membership declines in favor of profitability reinforces value-based care adoption.
Q2 earnings and raised guidance directly demonstrate the earnings power of value-based care, reinforced by analyst target raises and Zacks upgrade.
Growing adoption of value-based contracts by employers and government programs driving structural demand.
AI and data analytics improving care coordination and cost savings, as highlighted by management's plans to automate 80% of prior authorizations by 2027.
Defensive Rotation
评分: 65
Mixed-Bullish
With at 18.67 and markets cautious, defensive stocks with low beta and strong cash flows like UNH are relatively favored. UNH's 2.21% dividend yield and 0.63 beta provide portfolio stability. However, the stock's recent technical weakness introduces near-term uncertainty, and a rising rate environment (10Y at 4.64%) could cap upside. The long-term defensive growth profile remains intact.
The remains above 18, reinforcing demand for low-beta, cash-flow-rich names, while UNH's raised guidance provides fundamental support.
Elevated geopolitical tensions and inflation concerns keep some capital in defensives.
UNH's 2.82% YTD return with low volatility attracts total return seekers amid market uncertainty.
关键指标
23 项指标
市值
$379.28B
市盈率 (TTM)
31.4
远期市盈率
18.6
营收增速
0.4%
净资产收益率
14.2%
Beta 系数
0.63
完整指标集
另外 17 项指标
估值结构
估值倍数与现金流框架。
市销率
0.8
市净率
3.6
企业价值 / EBITDA
17.5
质量与资产负债表
利润率、杠杆与流动性。
毛利率
19.5%
营业利润率
7.1%
资产负债率
69.2
流动比率
0.78x
速动比率
0.47x
仓位与价格区间
空头仓位与52周区间位置。
流通盘空头占比
2.1%
空头回补天数
2.88x
52周最高
$461.62
52周最低
$234.60
距52周高点
-9.5%
距52周低点
78.0%
公司分类
板块与行业背景。
板块
Healthcare
行业
Healthcare Plans
其他信号
自由现金流
$22759749632.00
详细分析
估值
At $417.64, UNH trades at a forward of 18.6x on FY2027 consensus of $22.44, slightly above the 5-year median of 19x but justified by accelerated earnings growth. The ratio of 1.35 is attractive relative to projected growth (13.8% YoY in FY2027). FCF yield of 6.0% is compelling for a stable compounder. of 17.5x is reasonable given Optum's higher-margin profile. Relative to peers (median forward ~18x), UNH commands a justified premium. Analyst median target of $490 implies 17.3% upside; the high target of $529 suggests 26.7% upside.
资产负债表
Debt-to-equity of 69.2% is moderate. Total cash of $31.5B against total debt of $73.3B provides a net debt position of $41.9B. Operating cash flow of $27.0B and free cash flow of $22.8B offer strong coverage (OCF/debt ratio 0.37x). The balance sheet supports a 2.21% dividend yield and ongoing buybacks while funding growth investments.
增长
Trailing revenue growth of 0.4% reflects Medicare membership decline, but earnings growth is accelerating. Q2 2026 growth of 56.4% YoY (to $6.38) and raised FY2026 guidance imply 13-16% growth. Optum remains a key growth driver with higher margins. FY2027 estimates rose 8.1% in 30 days to $22.44, signaling strong momentum. Margins are expected to expand as commercial costs normalize and AI-driven efficiencies scale.
生意质量
UnitedHealth's vertical integration creates a durable competitive moat. Gross margin of 19.51%, operating margin of 7.13%, and of 14.15% reflect strong profitability. Institutional ownership at 86.2% signals wide recognition. Current ratio of 0.78 and quick ratio of 0.47 are industry-standard but acceptable given strong cash flows. The company's leadership in value-based care and employer-sponsored insurance provides a long-term edge.
资本配置
Capital allocation is disciplined: dividend yield of 2.21% with a payout ratio of 66.6%, plus share buybacks (at least $5B planned in 2026). Capital is also deployed into bolt-on acquisitions and internal investments (AI, prior authorization automation). Management's track record of balancing reinvestment with shareholder returns is excellent.
预期修正
Strongly bullish. For FY2027 (+1y), 8 upward revisions and 0 downward in the last 30 days. FY2026 estimates also rose (3 up, 2 down). The trend for FY2026 increased from $18.04 (90 days ago) to $19.81, and FY2027 from $20.28 to $22.44. Recent analyst actions include five major target raises (Morgan Stanley, KeyBanc, JPMorgan, Mizuho, Barclays) all maintaining positive ratings.